SuperCAP program to help cognition and daily functioning after COVID-19
Official title: Randomized Controlled Trial to Assess the Efficacy of a Supervised Computerized Active Program (SuperCAP) to Improve Cognition and Daily Functioning in People With Post-COVID-19 Condition
Run by Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · NCT07530757 · Data updated 2026-11-12
A digital program called SuperCAP is being tested to see if it can reduce disability in adults with long COVID compared to standard care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia Academic / other |
| Locations | 1 site (Badalona, Barcelona) |
| Status | Recruiting |
| Started | July 15, 2026 |
| Main results expected | November 2026 |
| Study ends | April 2027 |
| Registry record updated | September 11, 2026 |
| Trial ID | NCT07530757 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–65 with three or more persistent COVID-19 symptoms for at least three months and self-reported cognitive difficulties who can use a smartphone app-based program.
✕Probably not a fit
Participants without persistent cognitive symptoms or those unable to engage with a smartphone-based intervention may not experience benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized study compares a 13-week digital intervention (SuperCAP) plus psychoeducation to standard care in people with post-COVID condition. Participants will complete sessions that combine cognitive training, fatigue self-management, and multidisciplinary content, followed by a 12-week observation period. The main goal is to see if SuperCAP reduces disability more than control, measured by a ≥5 point improvement on WHODAS 2.0 from baseline to post-intervention. Secondary aims include effects on quality of life, daily functioning, cognition, emotional well-being, durability of benefits, and feasibility of implementation. The study uses an app-based delivery (eSalut) and includes adults aged 18–65 with persistent cognitive symptoms after COVID-19.
Why it matters
Potential benefit: If successful, participants could experience improved daily functioning and quality of life through cognitive support and self-management strategies.
How similar studies have gone: A prior randomized pilot showed feasibility and acceptability of the SuperCAP approach, justifying a larger trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of PCC, defined as the presence of three or more symptoms associated with COVID-19 infection for at least three months, not explained by other diseases. * Age 18 to 65 years. * Willingness to participate in an app-based intervention program aimed at improving daily Functioning in People Living with PCC. * Evidence of patient-reported cognitive difficulties emerging after COVID-19, operationalized as a WHODAS 2.0 Cognition Domain (D1) score \> 6 at baseline via RedCAP. * Digital proficiency defined as scoring ≥4 on MDPQ-16 item 2a (sending emails) and ≥3 on item 6a (using the device's app store) via RedCAP. * Self-reported ability to use a mobile application for approximately 15 minutes per day, 5 days per week, considering their current symptoms. * Possession of a personal smartphone compatible with the study mobile application (eSalut), with sufficient storage space and operating system version required for installation. Exclusion Criteria: * Inability to undergo neuropsychological tests or additional assessments. * Prior use of the SuperCAP program. * Current participation in a trial or program aimed at improving PCC symptoms. * Any condition that, in the investigator's opinion, could make participation unsafe, complicate interpretation of study results, interfere with achievement of study objectives, or otherwise affect the participant's ability to complete the study.
Where it's running
-
Fundació Lluita contra les Infeccions - Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain Recruiting
Study contacts
- Principal investigator: Anna Prats, PhD — Fundació Lluita contra les Infeccions
- Study coordinator: Anna Prats, PhD
- Email: aprats@lluita.org
- Phone: +34934657897
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Micro-choice-based approach to fatigue management
A small study in Basel will test a new four-day group program using micro-choices to help people with fatigue from multiple causes see if it’s doable, acceptable, and may help daily functioning.
-
Sonlicromanol for post-COVID fatigue with post-exertional malaise.
This trial will test whether taking sonlicromanol can reduce fatigue and post-exertional malaise in adults who meet WHO criteria for post-COVID and had a mild initial infection.
-
Cold water hydrotherapy to support rehabilitation in Post-COVID Syndrome
This tests whether adding cold water hydrotherapy to standard rehabilitation helps people with Post-COVID Syndrome improve their quality of life.
-
Rehabilitation program to reduce fatigue after COVID-19
This study is testing a new rehabilitation program called COVIDEx to see if it can help people with Long COVID feel less tired compared to standard care.
-
Registry for Long COVID in Children and Adults
This study is collecting information from children and adults who have Long COVID to better understand its effects and help improve care for those affected.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.